{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:47:27Z","timestamp":1792666047461,"version":"4.5.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"1095","license":[{"start":{"date-parts":[[2016,9,26]],"date-time":"2016-09-26T00:00:00Z","timestamp":1474848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,1,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Heart failure is one of the major public health challenges facing the Western world. Its prevalence is increasing as the population ages and modern techniques are implemented to manage cardiac disease. In response, there has been a sustained effort to develop novel strategies to address the high levels of associated morbidity and mortality. Indeed, agents that target the renin-angiotensin-aldosterone system (RAAS) have transformed the way in which we manage heart failure. Despite this, mortality in heart failure is poorer than in many malignancies and a large burden of morbidity and recurrent hospitalisation remains. Here, we review the role of RAAS modulation within the field of systolic heart failure. In particular, we provide practical guidance on using current RAAS blockade agents and focus on the recent emergence of new agents that promise additional substantial benefit to those living with left ventricular systolic dysfunction.<\/jats:p>","DOI":"10.1136\/postgradmedj-2016-134045","type":"journal-article","created":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T03:42:14Z","timestamp":1474947734000},"page":"29-37","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":52,"title":["The renin-angiotensin-aldosterone system in heart failure for the non-specialist: the past, the present and the future"],"prefix":"10.1093","volume":"93","author":[{"given":"Christopher","family":"Orsborne","sequence":"first","affiliation":[{"name":"North West Heart Centre, University Hospital of South Manchester , Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parminder S","family":"Chaggar","sequence":"additional","affiliation":[{"name":"North West Heart Centre, University Hospital of South Manchester , Manchester, UK"},{"name":"The University of Manchester , Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M","family":"Shaw","sequence":"additional","affiliation":[{"name":"North West Heart Centre, University Hospital of South Manchester , Manchester, UK"},{"name":"The University of Manchester , Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon G","family":"Williams","sequence":"additional","affiliation":[{"name":"North West Heart Centre, University Hospital of South Manchester , Manchester, UK"},{"name":"The University of Manchester , Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,9,26]]},"reference":[{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/hrt.2003.025270","article-title":"Clinical epidemiology of heart failure","volume":"93","author":"Mosterd","year":"2007","journal-title":"Heart"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.ejheart.2008.09.004","article-title":"Mode of death in patients with newly diagnosed heart failure in the general population","volume":"10","author":"Mehta","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1388-9842(00)00141-0","article-title":"More \u2018malignant\u2019 than cancer? Five-year survival following a first admission for heart failure","volume":"3","author":"Stewart","year":"2001","journal-title":"Eur J Heart Fail"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1161\/CIRCULATIONAHA.108.812172","article-title":"Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people","volume":"119","author":"Jhund","year":"2009","journal-title":"Circulation"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/CIRCOUTCOMES.110.957571","article-title":"Population impact of heart failure and the most common forms of cancer: a study of 1 162 309 hospital cases in Sweden (1988 to 2004)","volume":"3","author":"Stewart","year":"2010","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","article-title":"ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur Heart J"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1755-5922.2009.00094.x","article-title":"Neuroendocrine effects on the heart and targets for therapeutic manipulation in heart failure","volume":"27","author":"Chaggar","year":"2009","journal-title":"Cardiovasc Ther"},{"key":"2023041308090333400_","first-page":"1429","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators","volume":"327","year":"1992","journal-title":"N Engl J Med"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"issue":"1","key":"2023041308090333400_","first-page":"430","article-title":"The Survival and Ventricular Enlargement (SAVE) study: rationale and perspective","volume":"18","author":"Pfeffer","year":"1993","journal-title":"Herz"},{"key":"2023041308090333400_","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group","volume":"333","author":"K\u00f8ber","year":"1995","journal-title":"N Engl J Med"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","article-title":"Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group","volume":"355","author":"Flather","year":"2000","journal-title":"Lancet"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ejheart.2005.07.002","article-title":"Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice","volume":"7","author":"McMurray","year":"2005","journal-title":"Eur J Heart Fail"},{"key":"2023041308090333400_","volume-title":"The British National Formulary London: British Medical Association and the British Pharmacological Society"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1161\/01.CIR.0000038702.35084.D6","article-title":"Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: carvedilol as The Sun and center of the beta-blocker world?","volume":"106","author":"Wollert","year":"2002","journal-title":"Circulation"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1161\/01.HYP.33.2.613","article-title":"Recent progress in angiotensin II type 2 receptor research in the cardiovascular system","volume":"33","author":"Horiuchi","year":"1999","journal-title":"Hypertension"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0735-1097(01)01111-1","article-title":"Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease","volume":"37","author":"Petrie","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am J Hypertens"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0735-1097(00)00741-5","article-title":"The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure","volume":"36","author":"McClean","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(00)02602-7","article-title":"Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial","volume":"356","author":"Rouleau","year":"2000","journal-title":"Lancet"},{"key":"2023041308090333400_","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2023041308090333400_","volume-title":"Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction, Technology appraisal guidance","author":"National Institute for Health and Care Excellence","year":"2016"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/93\/1095\/29\/49840312\/postgradmedj-93-29.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/93\/1095\/29\/49840312\/postgradmedj-93-29.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T16:13:27Z","timestamp":1718813607000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/93\/1095\/29\/6984314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,26]]},"references-count":36,"journal-issue":{"issue":"1095","published-online":{"date-parts":[[2016,9,26]]},"published-print":{"date-parts":[[2017,1,1]]}},"URL":"https:\/\/doi.org\/10.1136\/postgradmedj-2016-134045","relation":{},"ISSN":["1469-0756","0032-5473"],"issn-type":[{"value":"1469-0756","type":"electronic"},{"value":"0032-5473","type":"print"}],"subject":[],"published-other":{"date-parts":[[2017,1]]},"published":{"date-parts":[[2016,9,26]]}}}